Moderna Phase 3 trial
The Latest
-
Moderna Enters First-Of-A-Kind Final Phase COVID-19 Vaccine Trials
Moderna stock rallied almost 10 percent and settled at 79.91 at Monday's close. 
Moderna stock rallied almost 10 percent and settled at 79.91 at Monday's close.
